Patient dosimetry in radionuclide therapy: the whys and the wherefores

Nuclear Medicine Communications

Volumn 26, Issue 7, 2005, Pages 593-599

  Thierens, Hubert M ^a   Monsieurs, Myriam A ^a   Bacher, Klaus ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Patient dosimetry; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 4 HEXADECYL 2,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL RE 188; IODINATED POPPYSEED OIL I 131; IODINATED POPPYSEED OIL RE 188; IODINE 131; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG;

ACCURACY; BONE MARROW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG SAFETY; FOLLOW UP; HUMAN; ISOTOPE LABELING; LIVER CELL CARCINOMA; METHODOLOGY; NEUROBLASTOMA; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION PROTECTION; RADIOTHERAPY; RELIABILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROTOXICOSIS; WHOLE BODY RADIATION;

HUMANS; NEOPLASMS; PROGNOSIS; RADIATION INJURIES; RADIATION PROTECTION; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 21344440300     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000167910.76718.ad     Document Type: Article

References (52)

1. McDougall IR. Systemic radiation therapy with unsealed radionuclides. Semin Radiat Oncol 2000; 10:94-102.
2. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000; 10:73.
3. 131I using Monte Carlo simulation. J Nucl Med 2002; 43:1101-1109.
4. Thomas SR. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm 2002; 17:83-99.
5. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40:37S-61S.
6. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy At Various Ages From Internal Photon Sources. ORNL Report ORNL/TM-8381. Oak Ridge, TN: Oak Ridge National Laboratory, 1987.
7. Loevinger R, Budinger TF, Watson EE. Mird Primer for Absorbed Dose Calculations. New York: The Society of Nuclear Medicine, 1991.
8. DeNardo GL, Hartmann Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm 2002; 17:107-118.
9. Liu A, Wiliams LE, Wong JYC, Raubitscek AA. Monte Carlo assisted voxel source kernal method (MAVSK) for internal dosimetry. J Nucl Med Biol 1998; 25:423-433.
10. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys 1996; 23:1523.
11. Yoriyaz H, Stabin MG, dos Santos A. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med 2001; 42:662.
12. Siegel JA. The role and options for dosimetry in clinical practice. Cancer Biother Radiopharm 2002; 17:69-70.
13. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of dosimetry in radioimmunotherapy planning and treatment dosing. Critical Rev Oncol Hematol 2001; 39:203-218.
14. Meredith R. Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response. Cancer Biother Radiopharm 2002; 17:83-99.
15. Clarke SEM. Radionuclide therapy of the thyroid. Eur J Nucl Med 1991; 18:984-991.
16. van Isselt JW, de Klerk JMH, van Rijk PP, van Gils APG, Polman LJ, Kamphuis C, et al. Comparison of methods for thyroid volume estimation in patients with Graves'disease. Eur J Nucl Med 2003; 30:525-531.
17. Crawford DC, Flower MA, Pratt BE, Hill C, Zweit J, McCready VR, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med 1997; 24:1470-1478.
18. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal disease. J Nucl Med 1993; 34:1632-1638.
19. Silver S. Radioactive Nuclides in Medicine and Biology. Philadelphia: Lea & Febiger, 1968.
20. Berg GEB, Michanek AMK, Holmberg ECV, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996; 37:228-232.
21. Coakley AJ. Thyroid stunning. Eur J Nucl Med 1998; 25:203-204.
22. Nordyke RA, Gilbert FI. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991; 32:411-416.
23. Becker DV, Hurley JR. The impact of technology on clinical practice in Graves' disease. Mayo Clin Proc 1972; 47:835.
24. Holm LE, Hall P, Wiklund KE. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83:1072-1077.
25. Goldman MB, Maloof F, Monson RR. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol 1988; 127:969-980.
26. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of Ionizing Radiation. UNSCEAR 2000 Report. New York: United Nations, 2000.
27. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6:469-476.
28. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, et al. Outcome after treatment of high risk papillary and non-Hurthle cell follicular thyroid carcinoma. Ann Intern Med 1998; 129:622-627.
29. Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (editors): Nuclear Medicine Annual. New York: Raven Press; 1983, pp. 329-381.
30. Maxon HR. The role of 131-I in the treatment of thyroid cancer. Thyroid Today 1993; 16:1.
31. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry guided radioactive iodine treatment in patients with metastatic thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44:451-456.
32. Benua RS, Cicale MR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol, Radium Ther Nucl Med 1962; 87:171-182.
33. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
34. Young Jr JL, Miller RW. Incidence of malignant tumours in US children. J Pediatr 1975; 86:254.
35. Seeger RC, Fonkalsrud E, Selch MT. Neuroblastoma. In: Haskell CM (editor): Cancer Treatment, third edition. Philadelphia: WB Saunders; 1990, 489-499.
36. Hoefnagel CA, Voute PA, De Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumours using iodine-131-metaiodobenzylguanidine. J Nucl Med 1987; 28:308-314.
37. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1991; 18:408-431.
38. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991; 18:308-316.
39. Tristam M, Abdulaziz S, Alaamer JS, Lewington VJ, Zivanovic MA. Iodine 131 metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. J Nucl Med 1996; 37:1058-1063.
40. 131I-MIBG post therapy scans. Eur J Nucl Med 2002; 29:1581-1587.
41. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002; 47:3211-3223.
42. 131I-MIBG. J Nucl Med 2001; 42:1713-1721.
43. Parkin MD, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
44. Raoul JL, Guyader D, Bretagne JF, Duvauferrier JF, Bourguet P, Bekhechi D, et al. Randomized control trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
45. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemo embolization versus intra-arterial injection of 131-I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepathology 1997; 26:1156-1161.
46. Lau WY, Leung TWT, Ho SKW, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial lipiodol iodine 131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353:797-801.
47. 131I-lipiodol therapy. Eur J Nucl Med 2003; 30:554-561.
48. 131I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Eur J Nucl Med 2002; 29:1311-1316.
49. 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002; 23:237-242.
50. 188Re for hepatic tumor therapy. Appl Radiat Isot 1996; 47:267-271.
51. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 2005; 46:60-66.
52. 131I-lipiodol in patients with hepatocellular carcinoma. J Nucl Med 2004; 45:612-618.